| Income Statement | 2025-09-30 | 2025-03-31 | 2024-09-30 | |
|---|---|---|---|---|
| Product sales, net | 3,256 | 3,606 | 3,865 | |
| Cost of goods sold | 1,677 | 1,948 | 2,087 | |
| Gross profit | 1,579 | 1,658 | 1,778 | |
| Research and development | 24 | 30 | 29 | |
| Selling, general and administrative | 1,830 | 2,139 | 2,090 | |
| Benefit from reversal of accrued payroll taxes | 0 | -522 | - | |
| Total operating expenses | 1,854 | 1,647 | 2,119 | |
| Operating loss | -275 | 11 | -341 | |
| Other expense, net | - | -151 | -115 | |
| Gain on extinguishment of debt | 0 | 38 | - | |
| Interest expense, net | 107 | - | - | |
| Loss before income taxes | -382 | -102 | -456 | |
| Income tax expense | 0 | 7 | - | |
| Net loss | -382 | -109 | -456 | |
| Earnings per share, basic | 0 | 0 | 0 | |
| Earnings per share, diluted, total | 0 | 0 | 0 | |
| Weighted average common shares outstanding, basic (in shares) | 184,264,000 | 184,264,000 | 182,261,000 | |
| Weighted average common shares outstanding, diluted (in shares) | 184,264,000 | 184,264,000 | 182,261,000 | |
CV Sciences, Inc. (CVSI)
CV Sciences, Inc. (CVSI)